Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
General Infectious Disease
When would you consider an all-oral regimen for patients with Whipple's disease instead of the typical parenteral treatment with ceftriaxone or meropenem followed by oral TMP/SMX?
Moos V, et al., PMID 39978372
Related Questions
What approximate portion of men develop infertility following a mumps infection?
Do you routinely continue dual antibiotic coverage or de-escalate to monotherapy based on peritoneal fluid culture sensitivities in patients with relapsing pseudomonas aeruginosa peritoneal dialysis peritonitis after peritoneal catheter removal?
What is your approach in managing patients with suspected super-infected pancreatic pseudocysts that are not yet mature enough for drainage?
Would you recommend intra-articular anti fungal administration for patients with a prosthetic knee infection due to Candida albicans who has undergone an antibiotic space placement as part of a 1.5 stage procedure?
Do you routinely recommend adjunctive rifampin therapy for the management of Staphylococcus aureus native vertebral osteomyelitis?
Do you routinely recommend an immunodeficiency work up in patients with ARDS due to influenza infection who develop invasive pulmonary aspergillosis?
Do you generally recommend device exchange/removal in patients with gram positive bacteremia in the setting of intra-aortic balloon bump or other mechanical circulatory devices?
Do you recommend low or intermediate dosing of TMP-SMX over high dosing for the initial treatment of non-disseminated pulmonary nocardiosis?
In a patient with a history of seropositive erosive RA who has undergone treatment for a periprosthetic joint infection and currently has an antibiotic spacer in place with clinical improvement, what is the appropriate timing and strategy for restarting DMARDs and/or biologic therapy to balance infection risk with RA disease control?
For patients with spinal hardware infections, in what circumstances do you recommend 12 weeks over 6 weeks of antimicrobial therapy?
